PTEN deficiency potentiates HBV-associated liver cancer development through augmented GP73/GOLM1
© 2024. The Author(s)..
BACKGROUND: Although hepatitis B virus (HBV) infection is a major risk factor for hepatic cancer, the majority of HBV carriers do not develop this lethal disease. Additional molecular alterations are thus implicated in the process of liver tumorigenesis. Since phosphatase and tensin homolog (PTEN) is decreased in approximately half of liver cancers, we investigated the significance of PTEN deficiency in HBV-related hepatocarcinogenesis.
METHODS: HBV-positive human liver cancer tissues were checked for PTEN expression. Transgenic HBV, Alb-Cre and Ptenfl/fl mice were inter-crossed to generate WT, HBV, Pten-/- and HBV; Pten-/- mice. Immunoblotting, histological analysis and qRT-PCR were used to study these livers. Gp73-/- mice were then mated with HBV; Pten-/- mice to illustrate the role of hepatic tumor biomarker golgi membrane protein 73 (GP73)/ golgi membrane protein 1 (GOLM1) in hepatic oncogenesis.
RESULTS: Pten deletion and HBV transgene synergistically aggravated liver injury, inflammation, fibrosis and development of mixed hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). GP73 was augmented in HBV; Pten-/- livers. Knockout of GP73 blunted the synergistic effect of deficient Pten and transgenic HBV on liver injury, inflammation, fibrosis and cancer development.
CONCLUSIONS: This mixed HCC-ICC mouse model mimics liver cancer patients harboring HBV infection and PTEN/AKT signaling pathway alteration. Targeting GP73 is a promising therapeutic strategy for cancer patients with HBV infection and PTEN alteration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of translational medicine - 22(2024), 1 vom: 08. März, Seite 254 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Fuqiang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 3.1.3.67 |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 27.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12967-024-04976-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369493230 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369493230 | ||
| 003 | DE-627 | ||
| 005 | 20240328000103.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240309s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12967-024-04976-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM369493230 | ||
| 035 | |a (NLM)38459588 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Fuqiang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PTEN deficiency potentiates HBV-associated liver cancer development through augmented GP73/GOLM1 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Although hepatitis B virus (HBV) infection is a major risk factor for hepatic cancer, the majority of HBV carriers do not develop this lethal disease. Additional molecular alterations are thus implicated in the process of liver tumorigenesis. Since phosphatase and tensin homolog (PTEN) is decreased in approximately half of liver cancers, we investigated the significance of PTEN deficiency in HBV-related hepatocarcinogenesis | ||
| 520 | |a METHODS: HBV-positive human liver cancer tissues were checked for PTEN expression. Transgenic HBV, Alb-Cre and Ptenfl/fl mice were inter-crossed to generate WT, HBV, Pten-/- and HBV; Pten-/- mice. Immunoblotting, histological analysis and qRT-PCR were used to study these livers. Gp73-/- mice were then mated with HBV; Pten-/- mice to illustrate the role of hepatic tumor biomarker golgi membrane protein 73 (GP73)/ golgi membrane protein 1 (GOLM1) in hepatic oncogenesis | ||
| 520 | |a RESULTS: Pten deletion and HBV transgene synergistically aggravated liver injury, inflammation, fibrosis and development of mixed hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). GP73 was augmented in HBV; Pten-/- livers. Knockout of GP73 blunted the synergistic effect of deficient Pten and transgenic HBV on liver injury, inflammation, fibrosis and cancer development | ||
| 520 | |a CONCLUSIONS: This mixed HCC-ICC mouse model mimics liver cancer patients harboring HBV infection and PTEN/AKT signaling pathway alteration. Targeting GP73 is a promising therapeutic strategy for cancer patients with HBV infection and PTEN alteration | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a GP73 | |
| 650 | 4 | |a Hepatitis B virus | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Intrahepatic cholangiocarcinoma | |
| 650 | 4 | |a Pten | |
| 650 | 7 | |a GOLM1 protein, human |2 NLM | |
| 650 | 7 | |a Membrane Proteins |2 NLM | |
| 650 | 7 | |a PTEN Phosphohydrolase |2 NLM | |
| 650 | 7 | |a EC 3.1.3.67 |2 NLM | |
| 650 | 7 | |a PTEN protein, human |2 NLM | |
| 650 | 7 | |a EC 3.1.3.67 |2 NLM | |
| 700 | 1 | |a Guo, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Na |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Mengjie |e verfasserin |4 aut | |
| 700 | 1 | |a Gai, Xiaochen |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Shuhui |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Pei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanan |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Huayu |e verfasserin |4 aut | |
| 700 | 1 | |a Jing, Yanling |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Di |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Zhongdong |e verfasserin |4 aut | |
| 700 | 1 | |a Zha, Xiaojun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hongyang |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Yilei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Fangming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hongbing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of translational medicine |d 2003 |g 22(2024), 1 vom: 08. März, Seite 254 |w (DE-627)NLM142679194 |x 1479-5876 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1 |g day:08 |g month:03 |g pages:254 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12967-024-04976-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 1 |b 08 |c 03 |h 254 | ||